GP 7

Drug Profile

GP 7

Latest Information Update: 08 Apr 2003

Price : $50

At a glance

  • Originator Lanzhou Medical College
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 08 Apr 2003 No development reported - Preclinical for Cancer in China (unspecified route)
  • 06 Jun 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 25 Jul 1996 Preclinical development for Cancer in China (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top